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ABSTRACT
Introduction: The incidence of hepatitis E
(HEV) genotype 3 is rising in developed coun-
tries. HEV infections are usually self-limiting,
but can become chronic in immunocompro-
mised patients. This might lead to rapid fibrosis
development even resulting in cirrhosis.
Chronic HEV is mainly described in patients
after solid-organ or hematological transplanta-
tions. We present the first case of HEV infection
in a patient with tuberous sclerosis complex
(TSC) treated with everolimus, a mammalian
target of rapamycin (mTOR) inhibitor.
Case: A 46-year-old male with TSC was referred
to the infectious diseases department with an
acute rise of liver enzymes during routine lab-
oratory check-up. He was diagnosed with an
acute HEV infection. His current treatment for
TSC was everolimus. After awaiting a
spontaneous clearance for 3 months, ever-
olimus was discontinued. Hereafter, the infec-
tion was cleared within another 3 months.
Discussion: Due to a favorable side-effect pro-
file, everolimus is gaining popularity as an
immunosuppressive therapy. However, in vitro
experiments suggest that inhibition of mTOR
leads to a significant increase in HEV replica-
tion. Thus far, there have been no clinical
reports of HEV infections in patients treated
with everolimus.
Conclusion: Due to higher dosing of ever-
olimus in TSC patients, they are more vulnera-
ble to the development of chronic HEV
infection. Periodic assessment of transaminases
in these patients is advised.
Keywords: Chronic hepatitis E; Everolimus;
Hepatitis E; mTOR-inhibitor; Tuberous
sclerosis complex
INTRODUCTION
Hepatitis E virus (HEV) infections are among
the most important causes of hepatitis world-
wide. Genotypes (GT) 1 and 2 are endemic in
developing countries and cause about 70,000
deaths per year [1]. However, HEV GT 3 and 4
are emerging in developed countries [2, 3]. HEV
GT3 is usually transmitted through consump-
tion of undercooked meat from infected ani-
mals, such as pork, deer and wild boar [4–6].
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However, other routes like blood transfusion
and vertical transmission have also been
described [7–11]. HEV infection results in
(a)symptomatic acute hepatitis which is usually
self-limiting within 4–6 weeks [5]. Patients with
an immunocompromised status due to
solid-organ or hematological transplantations
are an exception [5]. In these groups of patients,
HEV infection can develop into chronic HEV,
which can cause rapid progression of liver
fibrosis and cirrhosis [12, 13]. A new group of
immunocompromised patients at risk for HEV
infection are those treated with monoclonal
antibodies like rituximab and tocilizumab [14]
or non-transplant patients treated with
immunosuppressive drugs, like cyclosporine A
and everolimus [15]. Everolimus is, among
other things, used to treat malignant disease in
tuberous sclerosis complex (TSC). It is a mam-
malian target of rapamycin (mTOR) inhibitor
and suppresses immunity by several mecha-
nisms, one of which is blocking T cell activation
by cytokines. Here, we describe an HEV infec-
tion in a patient with tuberous sclerosis com-
plex (TSC) who was treated with everolimus. All
procedures followed were in accordance with
the ethical standards of the responsible com-
mittee on human experimentation (institu-
tional and national) and with the Helsinki
Declaration of 1964, as revised in 2013.
Informed consent was obtained from the
court-appointed mentor.
CASE
A 46-year-old male was referred to the infectious
diseases department with an acute rise of liver
enzymes during routine laboratory evaluation
(Table 1). His past medical history revealed
tuberous sclerosis complex, for which he was
treated with sirolimus since 2007 due to the
progression of subependymal giant cell astro-
cytoma and multiple renal angiomyolipomas.
This was switched to everolimus (10 mg per
day) in 2013 after two registration studies had
shown its safety and efficacy for these indica-
tions [16, 17]. At presentation (in 2015), the
patient had suffered fatigue and weight loss of
5 kg during the preceding 3 months. There was
no icterus, nausea or fever. A thorough food
history was taken, but revealed no obvious
route of transmission, such as the consumption
of red meat, wild boar or deer. The patient did
report consumption of well-cooked pork in the
past. There was no history of blood transfu-
sions. The patient had lived his entire life in a
non-endemic country with good sanitary
hygiene and there was no history of travelling
abroad. Physical examination was normal and
the liver was not palpable. An active HEV
infection was diagnosed though serum poly-
merase-chain-reaction (PCR; nucleic acids were
extraction with MP96 system; Roche Diagnos-
tics, Germany; and primers and probes based on
Zhao et al. [18]) with a cycle time of 23.41 cycles
(amplification by a Taqman 7500 instrument;
Applied Biosystems). After diagnosis, sponta-
neous clearance was awaited for a period of
3 months. However, since no spontaneous
clearance occurred (PCR positive, cycle time
25.54), everolimus therapy was discontinued.
Subsequent re-evaluation after another
3 months showed negative serum PCR and
normalization of liver enzymes. Hereafter,
everolimus therapy was restarted and no rise of
liver enzymes was seen during more than 1 year
follow-up (Fig. 1). During everolimus discon-
tinuation, the patient had no complaints indi-
cating progression of the giant cell astrocytoma.
Additionally, computed tomography of the
brain and kidneys following restart of ever-
olimus therapy showed no progression of the
brain tumor nor of renal angiomyolipomas.
DISCUSSION
This is the first report of chronic hepatitis E in a
patient with tuberous sclerosis complex treated
with the mTOR-inhibitor everolimus. Discon-
tinuation of everolimus, after awaiting unsuc-
cessful spontaneous clearance, resulted in the
clearance of HEV and normalization of liver
enzymes.
Due to its favorable side effect profile, ever-
olimus is gaining popularity and is used as
treatment for a variety of illnesses, such as
malignancies, tuberous sclerosis complex and
the Peutz–Jeghers syndrome, and after
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solid-organ or hematological transplantation.
Direct inhibition of mTOR and treatment with
everolimus were found to stimulate HEV repli-
cation inhumanhepatomacell lines invitro [19].
A significant increase inHEV replicationwas seen
after treatment with everolimus (dose 1 ng/ml)
and confirmed with doses of 10, 100 and
1000 ng/ml. Everolimus doses used for tuberous
sclerosis complex are 3–7 times higher than
when used as immunosuppression after trans-
plantation. The therapeutic range for everolimus
in TSC used in our clinic is between 3 and 10 ng/
ml. This might explain why higher doses of
everolimus are a risk factor for hepatitis E devel-
opment in these patients.Noanimal studieshave
been performed to assess the effect of everolimus
onHEV replication, and patient studies have not
yet identified everolimus as an influencing factor
for HEV. Therefore, it should be considered that,
apart from everolimus therapy, HEV persistence
in this case might have been influenced by other
factors, such as TSC-related or individual factors.
A similar stimulating effect on HEV replica-
tion in vitro has been found for cyclosporine A
and tacrolimus, while mycophenolic acid has
been shown to inhibit replication of HEV [20].
The latter was confirmed clinically in patients
after heart transplantation, where mycopheno-
late mofetil was found to protect against
chronic infections [21].
Table 1 Laboratory values
Laboratory test
(reference value)










AST (0–30 U/L) 430 137 25 36
ALT (0–35 U/L) 669 242 15 21
Bilirubin (3–21 lmol/L) 15 10 22 7
ALP (0–120 U/L) 267 147 77 102
GGTP (0–40 U/L) 243 145 24 20
LD (0–250 U/L) 450 NR 196 263
Albumin (35.0–50.0 g/L) 42.0 NR NR NR
Prothrombin time
(11.8–14.8 s)
13.0 NR NR NR
lmole micromole, L liter, U unit, g gram, ALP alkaline phosphatase, GGTP gamma-glutamyl transpeptidase, AST aspartate
aminotransferase, ALT alanine aminotransferase, LD lactate dehydrogenase, HEV hepatitis E virus, NR not reported































Fig. 1 Laboratory values during course of disease
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CONCLUSION
TSC patients receiving high-dose everolimus are
vulnerable to the development of chronic HEV
infection. Periodic assessment of transaminases
in these patients is advised.
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